Asset profile
Manfidokimab
Monoclonal antibody
Evidence outlook · registrational
Atopic Dermatitis: registrational readout pending
Entered Phase 3 on weak signal mid-stage evidence. No upcoming registrational readout date is posted to the registry — check News for topline announcements.
NCT06700499: The study was a 450-participant, open-label, single-arm trial with no placebo or active comparator, so it cannot directly determine efficacy or comparative safety. Its primary safety endpoint has no posted results, and the study design does not provide controlled evidence of benefit.
Also in development:Asthma · Phase 2
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.